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Abstract: Given that biosimilars are agents that are similar but not identical to the reference 
biopharmaceutical, this study aims to introduce and describe specific issues related to the 
economic evaluation of biosimilars by focusing on the relative costs, relative effectiveness, 
and cost-effectiveness of biosimilars. Economic evaluation assesses the cost-effectiveness 
of a   medicine by comparing the costs and outcomes of a medicine with those of a relevant 
comparator. The assessment of cost-effectiveness of a biosimilar is complicated by the fact 
that evidence needed to obtain marketing authorization from a registration authority does not 
always correspond to the data requirements of a reimbursement authority. In   particular, this 
relates to the availability of adequately powered equivalence or noninferiority studies, the need 
for comparative data about the effectiveness in a real-world setting rather than the efficacy in 
a structured setting, and the use of health outcome measures instead of   surrogate endpoints. 
As a biosimilar is likely to be less expensive than the comparator (eg, the   reference 
biopharmaceutical), the assessment of the cost-effectiveness of a biosimilar depends on 
the relative effectiveness. If appropriately designed and powered clinical studies demonstrate 
equivalent effectiveness between a biosimilar and the comparator, then a cost-minimization 
analysis identifies the least expensive medicine. If there are differences in the effectiveness of a 
biosimilar and the comparator, other techniques of economic evaluation need to be employed, 
such as   cost-effectiveness analysis or cost-utility analysis. Given that there may be uncertainty 
surrounding the long-term safety (ie, risk of immunogenicity and rare adverse events) and 
effectiveness of a biosimilar, the cost-effectiveness of a biosimilar needs to be calculated at 
multiple time points throughout the life cycle of the product.
Keywords: economic evaluation, cost-effectiveness, reimbursement, biosimilar, 
biopharmaceutical
Introduction
Biopharmaceutical medicines are reference or originator medicinal products made 
by or derived from living organisms using biotechnology (Figure 1).1 Biotechnology 
refers to the use of biological systems (eg, bacteria, yeast, and human cells) to 
identify, sequence, and manipulate DNA aimed at producing therapeutic and medical 
diagnostic products.2 The class of biopharmaceuticals has been available for more 
than 20 years and includes blood coagulation modulators, enzymes, erythropoietins, 
gonadotrophins, granulocyte colony-stimulating factors (G-CSFs), human growth 
hormones, human insulins, interferons, interleukins, monoclonal antibodies, tissue 
plasminogen activators, and vaccines. Biopharmaceuticals tend to have a large size and 
a complex structure and are manufactured from a unique line of living cells, making it ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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impossible to ensure an identical copy. This contrasts with 
chemical medicines, which tend to have a small size and 
simple structure and are manufactured using a predictable 
chemical process that generates identical copies.
Biopharmaceuticals represent a fast-growing segment of 
the pharmaceutical market, constituting 32% of   products in 
the development pipeline and 7.5% of marketed   medicines and 
accounting for around 10% of pharmaceutical expenditure.3 
The annual sales of the top ten biopharmaceuticals in 2006 
are illustrated in Figure 2. The biopharmaceutical market is 
expected to grow exponentially at more than 20% per year, as 
a result of a burgeoning pipeline, approval for more common 
conditions, increased utilization, and expanding indications.4 
This growth can be exemplified by the market access of 
new biopharmaceuticals that target larger populations in the 
presence of competitor medicines (eg, insulins for diabetes 
mellitus affecting 194 million patients worldwide).5
In the European Union, the first patents on biopharma-
ceuticals expired in 2001, and the first biosimilar   medicines 
or follow-on biologics were approved by European   Medicines 
Agency in April 2006. To date, biosimilars of recombinant 
human erythropoietins (epoetin alfa and epoetin zeta), G-CSFs 
(filgrastim), and human growth hormones (somatropin) have 
entered the European market. In the coming years, patents will 
expire on some major biopharmaceuticals such as interferons 
and insulins. Probably, this will lead to the market entry of a 
number of biosimilars in the not too distant future.
Biosimilars are agents that are similar but not identical 
to the reference biopharmaceutical (Figure 1). Therefore, 
a regulatory framework is in place in, for example, the European 
Union to assess the application for marketing authorization 
of biosimilars.6 In addition, a regulatory framework has been 
introduced in the United States in 2010, although it is not clear 
how these rules will be implemented and how they will play 
out in practice.7 In general, a biosimilar is registered if it is 
similar to the reference biopharmaceutical in terms of safety, 
quality, and efficacy. Dossiers of biosimilars tend to include 
data from clinical trials with a view to demonstrating similar 
safety and efficacy with the reference biopharmaceutical. 
In light of the variation between biotechnology   medicines, the 
marketing authorization process is specific to each product. 
For instance, the European Medicines Agency has published 
additional guidelines that relate specifically to biosimilars 
containing monoclonal antibodies8 and   biosimilars containing 
recombinant interferon β.9
Biotechnology
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Figure 1 Outline of biotechnology medicines.
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In addition to the factors mentioned above – the rapid 
growth of the biotechnology market, the imminent   patent 
expiry on several major biopharmaceuticals, and the 
establishment of regulatory frameworks – the key driver 
for the biosimilar market is likely to be cost containment 
pressures in health care systems in the context of aging 
populations and of the current financial and economic   crisis. 
For instance, the European Generic Medicines Agency 
has estimated that biosimilars generated annual savings 
of ∼€1.4 billion in the European Union in 2009.10
Economic evaluation serves to guide the implementation 
of safe and cost-effective medicines that support further 
health improvements, while containing health expenditure. 
Economic evaluation assesses the cost-effectiveness of a 
medicine by comparing the costs and outcomes of a   medicine 
with those of a relevant comparator.11 Evidence derived 
from economic evaluations is used to inform pharmaceutical 
reimbursement decisions in many countries. The requirement 
for economic evaluation fits within an overall trend toward 
evidence-based decision-making in health care.12
The results of an economic evaluation can be expressed 
in the form of an incremental cost-effectiveness ratio. This 
ratio relates the difference in costs between a medicine and 
the comparator to the difference in outcomes. The incre-
mental cost-effectiveness ratio can be represented as a point 
on the cost-effectiveness plane (Figure 3).11 On the horizontal 
axis, the difference in effectiveness (eg, life years) between a 
medicine and the comparator is portrayed. The vertical axis 
represents the cost difference between a medicine and the 
comparator. A medicine may have higher or lower costs and 
higher or lower effectiveness than the comparator, so that its 
point may fall into one of the four quadrants.
The incremental cost-effectiveness ratio can then be 
compared with a threshold incremental cost-effectiveness 
ratio, which reflects the maximum cost per unit of outcome 
that a health care payer is willing to pay for a medicine. This 
means that a medicine with an incremental cost-effectiveness 
ratio below the threshold value is likely to be accepted by a 
health care payer and a medicine with an incremental cost-
effectiveness ratio exceeding the threshold value is likely 
to be refused. Table 1 provides an overview of threshold 
incremental cost-effectiveness ratios in selected countries. 
Such threshold ratios are usually applied to medicines, but are 
relevant to any health technology. The gradient of the dashed 
line in Figure 3 represents a specific threshold incremental 
cost-effectiveness ratio. A medicine is cost-effective if its 
point estimate falls to the southeast of this dashed line.
The aim of this study is to introduce and describe specific 
issues related to the economic evaluation of   biosimilars. This 
study provides insight into the cost-effectiveness of   biosimilars 
to academic researchers, pharmaceutical   companies that set 
up biosimilar research and development programs, and 
policy makers who make decisions about reimbursement 
of biosimilars.
Methods
This study was based on a review of the international 
  literature focusing on the relative costs, relative   effectiveness, 
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and   cost-effectiveness of biosimilars. The literature review 
did not wish to identify and discuss all economic   evaluations 
of biosimilars, but rather drew on published economic 
evaluations with a view to identify and illustrate the factors 
affecting the cost-effectiveness of biosimilars. As such, the lit-
erature review of economic evaluations was not systematic.
Relevant studies were identified by searching PubMed, 
Embase, Centre for Reviews and Dissemination databases 
(Database of Abstracts of Reviews of Effects, National 
Health Service Economic Evaluation Database, and Health 
Technology Assessments Database), Cochrane Database of 
Systematic Reviews, and EconLit up to November 2010. 
Additionally, the bibliography of included studies was 
checked for other relevant studies. Search terms included 
‘biotechnology’, ‘biopharmaceutical’, ‘  biosimilar’, 
‘follow-on biologic’, ‘market access’, ‘research and 
development’, ‘registration’, ‘pricing’, ‘reimbursement’, 
‘health   economics’, ‘pharmaco-economics’, ‘economic 
evaluation’, and ‘  cost-effectiveness’ alone and in combi-
nation with each other.
The literature search included articles published in 
peer-reviewed journals. Additionally, the relevant congress 
abstracts were identified by searching Outcomes Research 
Digest, an electronic database of abstracts presented at the 
conferences of the International Society of Pharmacoeco-
nomics and Outcomes Research.
Results
Relative effectiveness
Relative effectiveness, in the context of an economic 
evaluation, refers to the differences in effectiveness between 
a biosimilar and the comparator. Registration authorities, 
such as the European Medicines Agency or the US Food and 
Drug Administration, approve the marketing authorization 
of a biosimilar based on the assumption that the biosimilar 
generates equivalent outcomes as the reference biopharma-
ceutical. What does equivalence mean for assessing relative 
effectiveness?
Biopharmaceuticals require multifaceted manufacturing 
and purification processes, and changes to the manufacturing 
process can result in differences in quality, safety, and efficacy 
(ie, ‘the process is the product’).13 When the manufacturer 
of a biosimilar establishes its own manufacturing process, 
this process is unlikely to be 100% the same as the process 
of the reference biopharmaceutical.6 Subtle differences arise 
because biotechnology medicines are derived from living 
organisms and some process features of the reference biop-
harmaceutical remain confidential even after patent expiry.14 
Current analytical techniques and clinical studies are not 
able to detect all potential differences in clinical outcomes 
between a biosimilar and the reference biopharmaceutical.15 
Although the risk of immunogenicity and rare adverse events 
in the long term is particularly relevant to biotechnology 
medicines, the time horizon of biosimilar studies submitted to 
registration authorities is usually not long enough to consider 
these potential effects. For instance, the European Medicines 
Agency guideline relating to somatropin biosimilars states 
that one-randomized controlled trial comparing the biosimilar 
and the reference biopharmaceutical for, at least, 6 months 
is required for marketing authorization.16
This implies that, in practice, a biosimilar may have 
lower or equal effectiveness than the reference biopharma-
ceutical. The case can also arise where a biosimilar is more 
effective than the reference biopharmaceutical (a so-called 
‘bio-better’ medicine).17 This may result from the fact that 
the biopharmaceutical is developed using a 15- to 20-year-old 
manufacturing process, whereas the biosimilar manufacturer 
makes use of the most recent manufacturing processes.
Evidence needed to obtain marketing authorization from 
a registration authority does not always correspond to the 
data requirements of a reimbursement authority for a number 
of reasons. First, to substantiate the claim of equivalence 
between a biosimilar and the reference biopharmaceutical, 
there is a need for adequately powered equivalence or non-
inferiority studies. Such studies are available for some, but 
not for all biosimilars. For instance, the European Medicines 
Agency has accepted evidence from pharmacokinetic and 
pharmacodynamic studies only (eg, for filgrastim and 
recombinant human insulins) in the absence of noninferiority 
Table  1  Threshold  incremental  cost-effectiveness  ratios  in 
selected countries
Country Threshold value  
in local currency
Threshold value   
in Euro
Australia35 AUS$42,000–$76,000  
per life year
€24,700–€44,700  
per life year
Canada36 CAN$20,000–$100,000  
per QALY
€12,700–€63,300  
per QALY
England/wales37 £20,000–£30,000  
per QALY
€22,800–€34,100  
per QALY
Netherlands38 €20,000–€80,000  
per QALY
€20,000–€80,000  
per QALY
New Zealand39 NZ$3000–15,000  
per QALY
€1400–€7200  
per QALY
United States40 US$50,000 per QALY €34,400 
per QALY
Notes:  Local  threshold  values  were  converted  into  Euro  using  market 
exchange rates.
Abbreviation: QALY, quality-adjusted life year.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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clinical studies. In addition, the European Medicines Agency 
may allow the extrapolation of data to another indication of 
the reference biopharmaceutical without an evaluation of the 
biosimilar in this new patient population.18
Second, as the cost-effectiveness of a biosimilar is calcu-
lated relative to a comparator, there is a need for   comparative 
data. However, clinical trials used for   registration purposes 
usually employ placebo as a comparator. In contrast, 
reimbursement authorities require that the biosimilar be 
  compared to the current standard treatment (eg, the   reference 
  biopharmaceutical). An indirect comparison can be set up 
using the evidence from placebo-controlled trials of the 
biosimilar and placebo-controlled trials of the reference 
biopharmaceutical, but such comparisons have a lower meth-
odological quality as a direct head-to-head clinical trial of 
the biosimilar and the reference biopharmaceutical.
Third, registration authorities demand clinical trials that 
demonstrate efficacy in a structured setting. However, reim-
bursement authorities require data on the effectiveness of a 
biosimilar in a real-world setting.19 For instance, the impo-
sition of strict patient inclusion/exclusion criteria in clinical 
trials of biosimilars or the enrollment of healthy volunteers 
in clinical trials of recombinant G-CSF biosimilars restricts 
the generalizability of health outcome results and limits the 
use of such data for reimbursement purposes.18 In addition, 
differences in treatment regimens between those studied in 
clinical trials and those applied in daily clinical practice may 
have a clinically relevant impact on health outcomes.
Finally, it should be noted that clinical trials used for reg-
istration purposes may employ surrogate outcome measures. 
For instance, clinical trials have measured the impact of an 
epoetin alfa biosimilar on patient hemoglobin levels.20 In 
contrast, reimbursement authorities wish to have data about 
primary health outcomes, such as mortality or quality of life. 
To address this issue, health-economic modeling approaches 
can be employed if there is evidence of the relationship 
between the surrogate endpoint and the health outcome.
Relative costs
The relative costs or the cost difference between a biosimilar 
and the comparator in an economic evaluation depends on 
the cost of the medicines and other costs associated with 
biotechnology therapy.
From a theoretical perspective, the relative costs should 
reflect the difference in opportunity costs (ie, the cost related 
to the next-best choice available with limited resources) 
between a biosimilar and the comparator. However, in 
practice, relative costs refer to the difference in medicine 
acquisition prices. On the one hand, comparisons based 
on acquisition prices rather than costs could be   misleading 
because, for example, a manufacturer who is currently 
charging a high price might be willing to reduce it substan-
tially in the face of competition. On the other hand, differences 
in acquisition prices between a biosimilar and the comparator 
are relevant to many reimbursement authorities.
With respect to chemical medicines, differences in 
  acquisition prices between originator and generic   medicines 
of up to 80% have been observed in countries such as 
Germany, the United Kingdom, and the United States.21,22 
However, the price differential between biosimilars and 
  biopharmaceuticals is likely to be smaller than that observed 
between originator and generic chemical medicines, given 
that biosimilars incur higher research and development costs. 
The developmental time for a generic medicine is around 
3 years, whereas this period increases from 6 to 9 years 
for a biosimilar.23 Generic medicines need to demonstrate 
bioequivalence only, whereas biosimilars need to conduct 
phase I and III clinical trials. Although there is no need to 
repeat all trials of the reference biopharmaceutical, the need 
to conduct some biosimilar trials enrolling several hundreds 
of patients involve   considerable expense and time: a US study 
has estimated that the costs of biosimilar trials would range 
from US$10 to $40 million.24 This study also reported that the 
required investment in biosimilar manufacturing processes 
amounts to US$250–$450 million. Furthermore, pharma-
covigilance programs are usually instituted to follow up safety 
and efficacy of a biosimilar once the product has entered the 
market, thereby increasing the prices further. Differences in 
the acquisition price between a biosimilar and the reference 
biopharmaceutical in the region of 15%–30% have been 
suggested in the literature.3,23,25 This price   differential can 
be substantial when applied to expensive biopharmaceuti-
cals, and it can be expected to increase as the acquisition 
price of biosimilars falls as they gain market share.26 For 
instance, it has been estimated that a 20% price reduction of 
five off-patent biopharmaceuticals would save the European 
Union more than €1.6 billion per year.27
Hospitals, the setting in which biosimilars tend to be pre-
scribed, are likely to negotiate discounts on official medicine 
prices. In other words, competition between manufacturers 
takes the form of discounting to the distribution chain rather 
than price competition. No data on discounts for biosimilars 
are publicly available, but some studies have investigated 
discounting in the sector of generic chemical medicines. 
This research indicated that generic medicine discounts 
ranged from 20% to 70% off the wholesaler selling price ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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in France, and maximum discounts exceeded 50% of the 
drug tariff price in the United Kingdom.28,29 Competition 
by discount may financially benefit hospitals, but is not 
  sustainable in the long run, as health care payers and patients 
are likely to capture only some of the potential savings from 
a   biotechnology medicines market where companies   compete 
on price. In addition, as economic evaluations draw on 
  official prices of the biosimilar and the biopharmaceutical, 
the calculated relative costs do not correspond with actual 
differences in the acquisition costs, and the cost-effectiveness 
of biosimilars is not calculated correctly.
Any potential differences in the (long-term) safety and 
effectiveness of a biosimilar and the reference biopharma-
ceutical may impose the need for additional health care, and 
generate health care costs and costs of productivity loss. 
This, in turn, is likely to influence the cost-effectiveness of 
a biosimilar.
Cost-effectiveness
An economic evaluation relates the relative costs of a 
medicine and the current standard treatment to their relative 
effectiveness.11 In some cases, this means that the cost-
effectiveness of a biosimilar needs to be established vis-à-vis 
the reference biopharmaceutical. In other cases, biosimilars 
have been developed for older biopharmaceuticals, for which 
second-generation biopharmaceuticals are now marketed and 
have become the standard treatment (eg, second-generation 
erythropoietins and second-generation G-CSFs).3 This 
implies that the cost-effectiveness of the first-generation 
biosimilar needs to be determined relative to the second-
generation biopharmaceutical.
This second case can be illustrated with the example of 
filgrastim for preventing febrile neutropenia. Filgrastim, 
the reference biopharmaceutical, has been marketed in the 
European Union since 1991, and five filgrastim biosimilars 
have entered the market since 2008 for the same indication. 
A long-acting pegylated form of filgrastim, pegfilgrastim, 
was registered by the European Medicines Agency in 2002. 
As pegfilgrastim has become the standard treatment to prevent 
febrile neutropenia, any economic evaluation of a filgrastim 
biosimilar should calculate its cost-effectiveness relative to 
pegfilgrastim. Assuming that the filgrastim biosimilar and 
biopharmaceutical have equal effectiveness, the requirement 
to use pegfilgrastim as comparator may negatively influence 
the cost-effectiveness of a filgrastim biosimilar, given that 
pegfilgrastim has been shown to be at least as effective as 
the filgrastim biopharmaceutical.30
If clinical studies demonstrate an equal   effectiveness 
profile of a biosimilar and the comparator, then a cost-
minimization analysis needs to be carried out and the least 
expensive medicine is chosen. In Figure 3, this means that 
the point estimate for cost-effectiveness is situated on the 
vertical axis where there is no difference in the effectiveness 
between the biosimilar and the comparator.
Cost-minimization analyses have been submitted to 
reimbursement authorities for biosimilars of epoetin alfa, 
filgrastim, and somatropin in the European Union. 
For instance, the Scottish Medicines Consortium approved 
the use of epoetin zeta (Retacrit®; Hospira UK Limited, 
Royal Leamington Spa, UK), a biosimilar to epoetin alfa, for 
the treatment of anemia associated with chronic renal failure 
in 2008.20 As two phase III trials showed clinical equiva-
lence for epoetin zeta when compared with epoetin alfa for 
the   surrogate endpoints of correction and maintenance of 
hemoglobin concentration, the economic evaluation took 
the form of a cost-minimization analysis. The evaluation 
  compared epoetin zeta with three other erythropoiesis-
stimulating agents and concluded that epoetin zeta would 
yield equivalent efficacy at similar or lower costs.
The Scottish Medicines Consortium also accepted a 
filgrastim biosimilar (Ratiograstim®; Ratiopharm GmbH, 
UIm, Germany) for use within the National Health Ser-
vice Scotland for the prevention of febrile neutropenia.31 
Equivalent efficacy of the biosimilar and the reference bio-
pharmaceutical in terms of duration of severe neutropenia 
was supported by one randomized controlled trial in breast 
cancer patients. The manufacturer argued that the conclu-
sions from the breast cancer trial were relevant to a range 
of different types of   underlying diseases and to the per-
formance of the biosimilar in general. The reimbursement 
application reported a cost-minimization analysis focusing 
on the costs of medicines and treatment of febrile neu-
tropenia associated with the biosimilar and the reference 
biopharmaceutical. This analysis predicted savings with the 
biosimilar of £322 per patient over an 84-day period. Two 
analyses were   conducted: the first used list prices of medi-
cines and the second applied   discounted prices. Finally, the 
Scottish Medicines   Consortium remarked that no data had 
been submitted comparing the biosimilar with the second-
generation biopharmaceutical, pegfilgrastim.
The National Institute for Health and Clinical   Excellence 
recommended the use of a somatropin biosimilar to treat child 
growth deficiencies in England and Wales in May 2010.32 
Head-to-head trials demonstrated comparable   efficacy of the ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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biosimilar and the reference   biopharmaceutical. In this case, 
where the two products are suitable, the Institute argued that 
the less expensive biosimilar should be chosen.
If there are differences in the effectiveness of a biosimilar 
and the comparator, other techniques of economic evaluation 
need to be employed, such as a cost-effectiveness analysis 
(eg, using life years as outcome measure) or a cost-utility 
analysis (eg, using quality-adjusted life years as outcome 
measure). Assuming that total costs of a biosimilar are 
lower than total costs of the comparator means that the point 
estimate for cost-effectiveness lies south of the horizontal 
axis in Figure 3. The point estimate can fall in quadrant 2, 
where the biosimilar is more effective and less expensive 
than the comparator and, thus, is cost-effective. If the point 
estimate falls in quadrant 3, the biosimilar is less effective 
and less expensive than the comparator, and the incremental 
cost-effectiveness ratio needs to be calculated. In this case, 
the biosimilar is cost-effective when its point estimate falls 
to the southeast of the dashed line representing a specific 
threshold incremental cost-effectiveness ratio.
Given that no reimbursement authority has issued 
guidelines about which technique of economic evaluation is 
appropriate to calculate the cost-effectiveness of a biosimilar 
and given that there may be uncertainty surrounding relative 
effectiveness (cfr. supra), submissions to reimbursement 
authorities may include a cost-minimization analysis as well 
as a cost-effectiveness or cost-utility analysis.15 Additionally, 
such exercises may carry out sensitivity analyses, exploring 
the impact of changes in relative effectiveness on the cost-
effectiveness of a biosimilar.
Recently, innovative reimbursement mechanisms have 
been introduced by health care payers such as risk-sharing 
arrangements. A risk-sharing arrangement is a scheme in 
which the manufacturer shares the risk with the health care 
payer that the product may not be effective for a particular 
patient. If the product does not have the expected effect, the 
company may lose some or all product revenue or needs 
to provide a replacement product.33 Such arrangements are 
instituted at the level of a defined patient population rather 
than a group of patients cared for by an individual institution 
or health care provider, may require physicians to be trained 
in the appropriate use of the product, and necessitate the 
implementation of a tracking system to follow up its use. 
As risk-sharing arrangements are in place for selected biop-
harmaceuticals in some European countries, they are likely 
to be rolled out to apply to biosimilars as well and, thereby, 
influence their cost-effectiveness.34
Due to potential concerns surrounding the long-term 
safety (ie, risk of immunogenicity and rare adverse events) 
and effectiveness of a biosimilar, there is a need to consider 
the cost-effectiveness of a biosimilar after a number of years 
following the admission to the reimbursement system in 
addition to the assessment of its cost-effectiveness at the time 
of the reimbursement application. Therefore, manufacturers 
need to explore setting up databases or observational studies 
to demonstrate the postlaunch cost-effectiveness of a 
  biosimilar based on phase IV trials.
Conclusions
As a biosimilar is likely to be less expensive than the 
comparator (eg, the reference biopharmaceutical), the 
assessment of the cost-effectiveness of a biosimilar depends 
on the relative effectiveness. If appropriately designed 
and powered clinical studies demonstrate equivalent 
  effectiveness between a biosimilar and the comparator, then 
a   cost-minimization analysis needs to be carried out and the 
least expensive medicine is chosen. If there are differences 
in the   effectiveness of a biosimilar and the comparator, other 
  techniques of economic evaluation need to be employed, such 
as cost-effectiveness analysis or cost-utility analysis. Given 
that there may be uncertainty surrounding the long-term 
safety and   effectiveness of a biosimilar, the cost-effectiveness 
of a biosimilar needs to be calculated at multiple time points 
throughout the life cycle of the product.
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